Non-Squamous Non-Small Cell Lung Cancer (NSCLC) is a type of lung cancer that is hard to treat and often results in death. This study is exploring if new medicines, livmoniplimab and budigalimab, can help when used with chemotherapy compared to another drug, pembrolizumab, with chemotherapy.

In the study, 840 adults from 200 places worldwide will participate over 55 months (about 4.5 years). There are two parts to the study:

• The first part has four groups, each trying different medicine combinations with chemotherapy.
• The second part has two groups, one with the best dose of the new drugs, and the other with a placebo, which is a harmless pill with no medicine.

The study includes regular visits to the hospital for checks and tests. This may be more work for participants compared to their regular treatment. To join, you must have NSCLC without certain gene mutations and not have had treatment for this type of cancer before. If you join, you will help researchers learn if these new medicines can help treat lung cancer better.

• Study lasts 55 months.
• Regular hospital visits required.
• Potentially higher treatment burden than usual care.